Rosetta Genomics : First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval

The Test Differentiates Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous-Cell Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90 Percent - This is the First CLIA Approved Test Which Leverages MicroRNAs' Sensitivity as Biomarkers for Accurate Diagnosis of Lung Cancer -
July 22 , 2008- Rosetta Genomics, Ltd. (NASDQ: ROSG) announces that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program. CUMC is now finalizing the commercial aspects of this test and will announce its clinical availability to patients nationwide once details are finalized later this year... Rosetta Genomics' Press Release -

Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer

June 6, 2008 - Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today a research collaboration with The University of Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA- based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.

Current treatment for lung cancer includes surgical resection which may be followed by adjuvant therapy. While patients with high risk of recurrence may benefit from adjuvant therapy, those with low risk of recurrence may be exposed to unnecessary toxicities. The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens... Rosetta Genomics' Press Release -

Rosetta Genomics : Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology

April 14, 2008- Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced it has signed an agreement with University of California, Irvine School of Medicine (UC Irvine), relating to the development and validation of diagnostic tests based on the company's microRNA technology. The tests are designed to differentiate squamous versus non-squamous lung cancer, differentiate mesothelioma from adenocarcinoma, and identify cancers of unknown primary (CUP) origin... Rosetta Genomics' Press Release -